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Abstract 
Deep insight on delta16HER2 splice variant and its role in HER2-overexpressing breast cancer. 
 
HER2-positive overexpressing 
breast cancer and targeted 
therapy 
HER2 is a tyrosine kinase receptor (RTK) 
belonging to the family of epidermal growth factor 
receptors which includes HER1 (EGFR), HER3 and 
HER4. 
 Members of this family are characterized by an 
extracellular binding domain (ECD), a 
transmembrane fragment and an intracellular 
tyrosine kinase domain (ICD) which is integral to 
downstream signaling, except in the case of HER3 
(Yarden and Pines, 2012).  
These RTKs are activated by both homo- and 
heterodimerization mainly induced by the binding 
of a specific ligand. The HER2ECD, unlike that of 
the three other HERs, can assume a fixed 
conformation resembling a ligand-activated state 
and permitting its dimerization in the absence of 
ligand (Cho et al., 2003; Yarden and Pines, 2012). 
HER2 is the preferred partner of dimerization of the 
other HER members and, together with HER3, 
enhances the most powerful mitogenic and survival 
signaling cascade through the activation of PI3K-
Akt and MAPK downstream pathways (Yarden and 
Pines, 2012).  
HER2 amplification and/or overexpression occurs 
in 20-25% of human breast cancers (BCs) and 
identifies a particularly aggressive BC subtype with  
enhanced proliferation, metastatic potential and 
subsequent decreased survival (Arteaga et al., 2011; 
Prat and Perou, 2011; Cancer Genome Atlas 
Network, 2012; Hurvitz et al., 2013). Based on 
HER2 overexpression in malignant breast tumor 
cells as compared to normal tissues, novel 
rationally designed targeted agents, such as 
trastuzumab (T), lapatinib and pertuzumab, have 
been introduced in the clinical management of BC 
patients (De et al., 2013; Krop, 2013). In particular, 
the humanized monoclonal antibody (MAb) T binds 
to the juxtamembrane region (subdomain IV) of 
HER2ECD and has been approved in combination 
with chemotherapy as the standard of care for 
HER2-positive metastatic BC, in early disease and 
also, very recently, in the neo-adjuvant setting 
(Arteaga et al., 2011; De et al., 2013). Although T 
administration induces significant clinical benefits 
in a consistent number of patients, tumors progress 
in a high percentage of cases after one year of 
treatment and develop de novo or acquired 
resistance (Rexer and Arteaga, 2012; Wong and 
Lee, 2012). Potential resistance mechanisms, 
including activation of compensatory signal 
transduction pathways (HER2 cross-talk with other 
RTKs and amplification of HER signaling and/or 
alterations of the PI3K/AKT pathway) or defects in 
apoptosis and cell cycle control, have been 
demonstrated in in vitro models (Rexer and 
Arteaga, 2012) but await clinical validation.  
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Table 1. HER2 isoforms. 
 
Interestingly, recent preclinical studies suggest that 
HER2-overexpressing tumors able to evade T 
activity continue to exert HER2 oncogenic action as 
they retain HER2 amplification and overexpression 
(Hurvitz et al., 2013; Krop and Burstein, 2013). A 
significant contribution to T resistance could also 
derive from genetic or molecular events that lead to 
an increase in HER2 oncogenic potential and/or 
influence T binding to the receptor (Rexer and 
Arteaga, 2012). Indeed, different isoforms of the 
HER2 receptor have been identified in human BC 
deriving from alternative initiation of translation or 
splicing and proteolytic shedding (Table 1) and are 
not recognized by the humanized antibody (Arribas 
et al., 2011; Garrett and Arteaga, 2011; Rexer and 
Arteaga, 2012). 
delta16HER2 splice variant 
It is widely accepted that wild-type (WT) full-
length HER2 gene amplification is necessary, but 
not sufficient, to induce transformation (Slamon et 
al., 1989). Indeed, transgenic expression of the 
mammary-specific rat proto-oncogene HER2/neu 
generates tumors only when the protein shows 
alterations in the ECD, such as in-frame deletions 
or insertions of cysteine residues inducing 
conformational changes in the juxtamembrane 
region of WT HER2/neu receptor (Siegel et al., 
1994; Ursini-Siegel et al., 2007). The consequent 
cysteine residues imbalance plays a primary role in 
the regulation of HER2 catalytic activity because it 
induces receptor activation, promoting constitutive 
homodimerization through stable intermolecular 
disulfide bonds formation (Kwong and Hung, 1998; 
Chan et al., 1999; Siegel et al., 1999; Ursini-Siegel 
et al., 2007). In this context, different studies 
reported the constitutive expression of a human 
HER2 alternative splice isoform which carries an 
in-frame deletion in the same mutated region of the 
rat HER2/neu proto-oncogene (Kwong and Hung, 
1998; Siegel et al., 1999). This splice variant  
produces an aberrant receptor that lacks exon 16 
(delta16HER2) (Figure 1) and, in turn, 16 amino 
acids (634-649) in the HER2ECD (domain IV), 
including two relevant cysteine residues close to the 
T-binding epitope. The deletions result in stable 
constitutively active homodimer formation, 
enhanced multi-signaling activity and accelerated 
transformation (Kwong and Hung, 1998; 
Castiglioni et al., 2006; Mitra et al., 2009; Marchini 
et al., 2011; Alajati et al., 2013). 
- delta16HER2 splice variant and HER2-driven 
transformation 
In our previous analysis of 46 human HER2-
positive BCs, we found that delta16HER2 was 
constitutively co-expressed with WT HER2 in 
~90% of the BCs and its transcript represented 4-
9% of total WT HER2 mRNA (Castiglioni et al., 
2006), suggesting a possible role for this variant in 
WT HER2-driven tumorigenesis. Analysis of an 
additional 57 human primary BCs (Figure 2) 
showed that increasing WT HER2 transcript levels 
were correlated with a proportional enhancement of 
delta16HER2, thereby allowing it to contribute to 
BC progression. We also showed that 
delta16HER2-positive NIH3T3 and HEK293 
transfectants, but not their counterparts ectopically 
expressing WT HER2, constitutively expressed 
active disulfide-bridged homodimers and that only 
mice xenotransplanted with delta16-transfectants 
developed tumors (Castiglioni et al., 2006). Thus, 
WT HER2 requires additional genetic alterations to 
induce neoplastic transformation. More recently, 
Mitra et al. (2009) showed that delta16HER2-
overexpressing MCF7 human BC transfectants 
expressed stable dimers and were more invasive 
than WT HER2-transfected MCF7 cells. 
In addition, exogenous expression of delta16HER2 
in comparison to WT HER2 resulted in an 
increased activation of multiple downstream 
signaling pathways involving FAK, PI3K/Akt, 
MAPK and Src kinase. 
delta16HER2 splice variant and its role in HER2-overexpressing breast cancer Ghedini GC, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 528 
 
Figure 1. Schematic representation of the alternative delta16HER2 splice form of the human HER2 gene with an in-frame 
deletion of exon 16. 
 
Interestingly, those studies also revealed a direct 
correlation between node status and delta16HER2 
mRNA expression (Mitra et al., 2009), implicating 
delta16HER2 in human BC progression. Further 
confirmation of delta16HER2 intrinsic oncogenicity 
came from our recent generation a mouse line 
transgenically expressing the human delta16HER2 
variant using a bicistronic vector encoding both 
delta16HER2 and luciferase reporter genes under 
the MMTV promoter (Marchini et al., 2011). Our 
transgenic line was characterized by a higher tumor 
incidence as well as a shorter latency (about 8 
weeks of age) compared to the MMTVhuHER2 
transgenic model, which developed human WT 
HER2-overexpressing spontaneous mammary 
tumors after 28 weeks of age (Finkle et al., 2004; 
Marchini et al., 2011). The delta16HER2 variant 
was expressed on mammary tumor cells as cell 
surface-associated phosphorylated stable 
homodimers and monomers, and its downstream 
signals were significantly coupled to an activated 
Src kinase. In this transgenic model, about 5 copies 
of the delta16HER2 transgene were sufficient to 
drive early transformation in contrast to 30-50 
copies of WT HER2 transgene needed to develop 
mammary tumors in the MMTVhuHER2 model 
(Finkle et al., 2004; Marchini et al., 2011). Very 
recently, Alajati et al. (2013) provided further in 
vitro evidence that delta16HER2 is able to increase 
invasion and proliferation and also to decrease 
apoptosis either in two- or three-dimensional 
conditions. Consistent with our previous findings 
(Castiglioni et al., 2006), orthotopically injected 
delta16HER2-transfected MCF10A and MCF7 cells 
were shown to be more tumorigenic than WT 
HER2-transfected cells (Alajati et al., 2013). The 
same authors applied proteomic and genomic 
platforms finding a panel of phosphorylated 
signaling transducers and developed a 
delta16HER2-gene signature which was associated 
with ER-negative, high grade and metastatic BC 
patients. However, because the delta16HER2 
signature was analyzed within a dataset including 
all BC subtypes, its usefulness in the clinical 
management of HER2 BC patients remains unclear. 
- delta16HER2 susceptibility to anti-tumor 
therapies 
We reported that engineered delta16HER2-
HEK293 cells expressing constitutively active cell 
surface disulfide-bound homodimers bound T with 
low efficiency compared to other anti-HER2ECD 
MAbs (Castiglioni et al., 2006), suggesting 
potential delta16HER2-mediated interference with 
T clinical benefits (Sasso et al., 2011; Pupa et al., 
2011). Moreover, Mitra et al. (2009) showed that 
delta16HER2-positive cells were resistant to in 
vitro T treatment compared to WT HER2-positive 
cells and, in a small cohort of HER2-
overexpressing human BC cases, also observed that 
the aggressive features driven by delta16HER2 
were mediated by activated Src, which is 
considered a common node of T-resistance 
mechanisms (Zhang et al., 2011; De et al., 2013). 
Indeed, in vitro treatment of delta16HER2-
engineered tumor cells with dasatinib, a multi-
BCR/Abl and Src family tyrosine kinase inhibitor, 
led to deactivation of delta16HER2 and its 
tumorigenic capacity (Mitra et al., 2009).  
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Figure 2. Correlation between quantitative real time-PCR threshold cycles obtained from cDNA amplification of 
delta16HER2 and WT HER2 genes in 57 human BC samples was analyzed by linear regression and Pearson correlation 
coefficient r. 
 
Indeed, our studies to test the in vitro therapeutic 
effects of dasatinib on constitutively expressing 
delta16HER2-positive mammary tumor cells with 
highly activated Src kinase expression showed that 
delta16HER2 cells were significantly more 
sensitive to this agent than were WT HER2 
mammary tumor cells (manuscript in preparation). 
We previously found that delta16HER2 monomers 
and homodimers were dephosphorylated after in 
vitro treatment with another tyrosine kinase 
inhibitor, emodin, which interacts with several 
molecular targets, including NF-κB, HIF-1α, 
AKT/mTOR, STAT3, CXCR4, topoisomerase II, 
p53, p21 and also HER2 (Castiglioni et al., 2006; 
Shrimali et al., 2013). Together, these results 
suggest the potential efficacy of including tyrosine 
kinase inhibitors in therapeutic regimens directed 
against delta16HER2.  
On the contrary, in a pilot in vivo experiment with a 
xenograft model, Alajati et al. (2013) observed that 
delta16HER2-transfectants orthotopically injected 
in mammary glands of immunodeficient mice were 
able to metastasize to lungs and were found to be 
sensitive to T treatment.  
Notably, delta16HER2 expression has also been 
reported in 30% of estrogen receptor (ER)-positive 
BC patients who are most commonly treated with 
the selective ER modulator tamoxifen (Cittelly et 
al., 2010a). Indeed, half of HER2-expressing 
tumors are also ER-positive and the majority of 
these encounter tamoxifen resistance and estrogen-
independent growth (Sasso et al., 2011). Cittelly et 
al. (Cittelly et al., 2010a; Cittelly et al., 2010b) 
showed that in HER2- and ER-positive BCs, 
delta16HER2 promotes tamoxifen resistance in 
both in vitro and in vivo pre-clinical models. 
Specifically, they found that delta16HER2-
transfected cells treated with tamoxifen upregulated 
Bcl-2 by downregulating miR-15 and 16, which 
specifically target and repress Bcl-2, and that tumor 
growth of delta16HER2-xenografts was resistant to 
endocrine therapy and independent of estrogen 
(Cittelly et al., 2010a). In delta16HER2-transfected 
cells, they also observed the decrease in miR-342, 
which was also downregulated in primary BCs 
refractory to tamoxifen treatment (Cittelly et al., 
2010b). 
- delta16HER2 and the tumor microenvironment 
The recent wealth of literature showing that not 
only deregulated cancer cell proliferation but also 
alterations in the tumor microenvironment can 
influence solid tumor growth has raised the 
possibility for new anti-cancer strategies including 
interfering with transformed cell proliferative 
processes and blocking of tumor cell-host 
microenvironment interactions (Eccles, 2010). 
Indeed, the existence of a significant relationship 
among unbalanced extracellular redox state, cancer 
cell aggressiveness and response to cancer therapy 
has been described (Pelicano et al., 2004; 
Trachootham et al., 2009), raising the potential 
efficacy of a novel anti-tumor therapeutic strategy 
based on the targeting of the acidic extracellular pH 
(pHe) (Neri and Supuran, 2011), since tumor pHe 
drives cell proliferation, promotes metastatic 
potential and supports chemoresistance (De Milito 
et al., 2010). In particular, proton pump inhibitors 
(PPIs), which are currently used in the anti-acid 
treatment of peptic disease, might inhibit 
acidification of the tumor microenvironment while 
increasing tumor cell sensitivity to cytotoxic agents 
in different oncotypes (Luciani et al., 2004; 
Spugnini et al., 2010). Targeting microenvironment 
conditions, we previously showed that 
delta16HER2-HEK293 cells treated with increasing 
doses of the anti-oxidant β2-mercaptoethanol 
restored T binding to the HER2 receptor 
(Castiglioni et al., 2006; Pupa et al., 2011). 
delta16HER2 splice variant and its role in HER2-overexpressing breast cancer Ghedini GC, et al. 
 
 
 
 
 
Atlas Genet Cytogenet Oncol Haematol. 2014; 18(7) 530 
Moreover, our preliminary data (manuscript in 
preparation) show that the treatment of 
constitutively expressing delta16HER2-positive 
mammary tumor cells with PPIs modulates 
delta16HER2 homodimer expression and activation 
levels. Together, the findings point to the promise 
of improved management of HER2-positive BC 
patients through novel therapeutic strategies that 
include both PPI and agents, such as 
phenylethylisothiocyanate, PEITC and a 
glutathione disulfide mimetic, NOV-002, which are 
under investigation in our delta16HER2-positive in 
vitro and in vivo models, able to interfere with 
exacerbated extracellular microenvironment 
conditions. 
Conclusions 
Expression of the constitutive delta16HER2 splice 
variant represents an important genetic event 
guiding HER2-driven neoplastic transformation. 
Indeed, tumor-related alternative splicing could be 
indicative of splicing patterns specific to malignant 
breast tissue and could induce oncogenic 
transformation or favor cancer cell survival through 
resistance to therapy (Jackson et al., 2013). In vitro 
data suggest that delta16HER2 represents one of 
the potential mechanisms of T resistance.  
While it is tempting to speculate that delta16HER2-
expressing BC patients will benefit from aggressive 
therapeutic regimens (Jackson et al., 2013), current 
clinical diagnostic techniques to identify patients 
with HER2 overexpression or amplification fail to 
distinguish between WT HER2 and delta16HER2 
and all the other HER2 isoforms (Ward et al., 
2013).  
Moreover, screening assays and reagents to 
evaluate delta16HER2 expression levels in human 
BCs (Sasso et al., 2011; Pupa et al., 2011) in order 
to predict treatment response (Jackson et al., 2013) 
and reach the final goal of personalized cancer 
therapy remain to be developed. The availability of 
transgenic mouse models will enable further studies 
to elucidate the pathobiological roles of the 
constitutively activated HER2 splice variant both in 
mammary tumorigenesis and in the susceptibility to 
anti-HER2 targeted therapies and also as a novel 
target for the improved management of HER2-
positive disease. 
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